Gene Discovery in CHB Patients to Identify Unknown Pathways That Lead to B and NK Cell Deregulation

Status: Recruiting
Location: See all (3) locations...
Intervention Type: Other
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

Natural Killer (NK) and B cell immune responses occur during the early stages of infection and are essential to eradicate it. Yet, chronic hepatitis B (CHB) infection occurs because the antiviral immune response is insufficient. In both NK and B cell studies we will explore the genetic alterations that occur during the varied chronic stages of the disease. We believe that our findings will allow us to understand the molecular signature of NK and B cells in the context of HBV infection.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: t
View:

• Male or female, age ≥18 years old

• HBV infection or chronic HBV infection untreated or treated with a nucleoside or nucleotide analog

• Willing and able to provide written informed consent

• Affiliated with a social securityregimen

⁃ Healthy volunteer must meet all of the following inclusion criteria to be eligible for participation in this study:

• Male or female, age between 18 and 80 years

• Willing and able to provide written informed consent

Locations
Other Locations
France
Centre d'Investigation Clinique
RECRUITING
Limoges
Limoges University Hospital
RECRUITING
Limoges
Hospice civils de Lyon
NOT_YET_RECRUITING
Lyon
Contact Information
Primary
Véronique LOUSTAUD-RATTI, MD
veronique.loustaud-ratti@unilim.fr
+335 55 05 66 84
Time Frame
Start Date: 2025-08-12
Estimated Completion Date: 2028-10-01
Participants
Target number of participants: 140
Treatments
Other: HBV patient
a blood sample is done during a follow-up visit
Other: healthy volunteers
a blood sample
Related Therapeutic Areas
Sponsors
Leads: University Hospital, Limoges
Collaborators: National Agency for Research on AIDS and Viral Hepatitis (ANRS)

This content was sourced from clinicaltrials.gov